The Business Research Company’s Cell Therapy Global Market Report 2021: COVID-19 Growth And Change to 2030

Thermo Fisher Scientific Inc. and the University of California, San Francisco (UCSF) formed a strategic alliance to accelerate the development and manufacturing of cell-based therapies. The global cell therapy market is expected to grow by double-digits CAGR for the next ten years, according to the Global Market Model, the most efficient competitive intelligence database by The Business Research Company.

Under the collaboration, Thermo Fisher will build and operate a 44,000-square-foot, state-of-the-art cell therapy development, manufacturing, and collaboration center in leased space on UCSF’s Mission Bay campus, which includes biomedical research facilities and hospitals. This facility, expected to be operational by 2022, can provide biopharma customers & UCSF researchers access to Thermo Fisher’s broad portfolio of Cell Therapy Systems (CTS) reagents, consumables, instrumentation, and related software solutions. The site will offer clinical and commercial cGMP cell therapy manufacturing services, along with associated technology development support, to UCSF and other partners.

The key executives at Thermo Fisher Scientific and UCSF stated that the collaboration aids in providing integrated, end-to-end cost-effective solutions to potential biopharma companies that accelerate the adoption of cell therapies, ultimately improving patient access to these transformative treatments. Further, these cell therapies lead to breakthrough treatments for many disease conditions.

As per the Global Market Model, the global cell therapy market size is expected to grow from $7.2 billion in 2020 to $7.82 billion in 2021 at a compound annual growth rate (CAGR) of 8.6%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $12.06 billion in 2025 at a CAGR of 11%.

Cell therapy can benefit patients suffering from spinal cord injuries, type 1 diabetes, Parkinson’s disease (PD), heart disease, cancer, and osteoarthritis. According to Cancer Research UK, in 2018, 17 million cancer cases were added to the existing list, and according to the International Diabetes Federation, in 2019, 463 million were living with diabetes. According to the Parkinson’s Foundation, every year, 60,000 Americans are being diagnosed with PD, and more than 10 million people are living with PD worldwide. The growing prevalence of chronic diseases increased the demand for cell therapies and contributed to the growth of the market.

The global cell therapy market report by TBRC is segmented as below:

1) By Technique: Stem Cell Therapy, Cell Vaccine, Adoptive Cell Transfer (ACT), Fibroblast Cell Therapy, Chondrocyte Cell Therapy

2) By Therapy Type: Allogeneic Therapies, Autologous Therapies

3) By Application: Oncology, Cardiovascular Disease (CVD), Orthopedic, Wound Healing, Others

The Cell Therapy Global Market Report is one of a series of new reports from The Business Research Company that provides cell therapy market overviews, analyzes and forecasts cell therapy market size, share, cell therapy market players, cell therapy market segments and geographies, the market’s leading competitors’ revenues, profiles and market shares.

About The Author

Ravikiran has 12 years research experience in Biotechnology. He extensively worked with such companies/institutions as Ernst and Young (EY), DuPont and Center For Cellular & Molecular Biology (CCMB), Hyderabad. Ravikiran holds bachelor’s and master’s degrees in Biotechnology and Certification in Clinical Research from Institute of Clinical Research India (ICRI). In 2006, he took an advanced course in Bioinformatics at the Indian Institute of Chemicals Technology (IICT). Some of the clients he has worked for include Asahi Kasei Corporation, Fujifilm, and Sanofi Aventis. At TBRC, key projects he was involved in include a market study for bovine mastitis detection kits and research on multivalent pediatric vaccines.

About The Global Market Model

The Global Market Model is the world’s most comprehensive database of integrated market information available. The ten-year forecasts in the Global Market Model are updated in real time to reflect the latest market realities, which is a huge advantage over static, report-based platforms.

Interested In Knowing More About The Business Research Company?

The Business Research Company is a market intelligence firm that excels in company, market, and consumer research. Located globally it has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services, chemicals, and technology. The Global Market Model is The Business Research Company’s flagship product.

Contact Information

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 8897263534

Americas: +1 315 623 0293

Email: info@tbrc.info

Follow us on LinkedIn: https://in.linkedin.com/company/the-business-research-company

Follow us on Twitter: https://twitter.com/tbrc_info